Last reviewed · How we verify
Tegileridine
Tegileridine, marketed by Yuwei Qiu, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that may provide a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Tegileridine |
|---|---|
| Also known as | Tegi |
| Sponsor | Yuwei Qiu |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU) (PHASE2)
- Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery (PHASE4)
- Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection (NA)
- Determination of the Effective Dose of a Single Intravenous Dose of Tegileridine Fumarate for Postoperative Analgesia After Orthopedic Surgery: A Up-and-Down Sequential Allocation Study (PHASE4)
- Clinical Study of Equivalent Doses of Oxycodone or Tegileridine on Patients Undergoing Gynecological Laparoscopic Hysterectomy (PHASE4)
- Clinical Study on the Effect of Tegileridine on Postoperative Pain in Patients Undergoing Abdominal Surgery. (PHASE4)
- Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery (PHASE4)
- To Evaluate the Efficacy and Safety of Tegileridine and Oliceridine Injections in the Treatment of Postoperative Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegileridine CI brief — competitive landscape report
- Tegileridine updates RSS · CI watch RSS
- Yuwei Qiu portfolio CI